Telix Pharmaceuticals Limited · ASX:TLX
Telix Pharmaceuticals — Q1 2023 Earnings Presentation
21 slides from Telix Pharmaceuticals's earnings presentation, Apr 17, 2023
Slide 1: Q1 2023 Quarterly Business Update
Q1 2023 Quarterly Business Update Telix Pharmaceuticals (ASX:TLX) 17 April 2023 Illustration of TLX250-CDx binding to carbonic anhydrase IX
Slide 2: Disclaimer
Disclaimer The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. No representation or warranty, express or implied,
Slide 3: Q1 2023 Highlights
Q1 2023 Highlights Advancing our value-creating assets Continued growth in prostate • U.S. demand continues to grow; revenue from Illuccix sales up 27% cancer imaging (Illuccix®) • Commercial and regulatory progress in key global markets Commercialisation plans for • Positive meeting with FDA for TL
Slide 4: Q1 2023 Financial metrics
Q1 2023 Financial metrics Rapid revenue growth underpins balance sheet improvement Total revenue comparison to previous periods Q1 2023 $100.1M Up 27% on Q4 2022 Net operating Gross Customer Cash Q4 2022 cash inflow margin receipts balance $79.0M $2.4M $121.4M 63% $83.2M Improvement of In line with
Slide 5: Illuccix Commercial Update
Illuccix® Commercial Update
Slide 6: U.S. market demand for Illuccix continues to grow
U.S. market demand for Illuccix continues to grow Illuccix performing strongly in the growing PSMA-PET1 imaging market • Revenue from U.S. sales of Illuccix up 27% to $97.5M (US$66.2M) on the prior quarter, despite a “short” Revenue from U.S. sales of Illuccix (AU$M) 110.0 (90 day) quarter 100.0 Rei
Slide 7: Illuccix global rollout
Illuccix global rollout Our ability to deliver globally is a key advantage Telix is delivering PSMA-PET imaging on a commercial and pre- commercial1 basis in major global markets. Recent updates: • Americas: Commercial launch underway in Canada with partner Isologic2 • EMEA: Marketing Authorisation
Slide 8: Financial Commentary
Financial Commentary OTelix —— ae
Slide 9: Positive operating cash flow trend continues
Positive operating cash flow trend continues Second consecutive quarter of net cash inflow from operating activities Cash flow from operating activities ($M) • Cash increases to $121.4M at 31 March 2023 5.0 1.6 2.4 (compared to $116.3M at 31 December 2022) (5.0) (5.3) • Quarterly operating cash flow
Slide 10: Sales performance and controlling operating expenditure
Sales performance and controlling operating expenditure Funding focused investment in priority programs Product-related revenue ($M) and gross margin percentage • Gross margin has stabilised from Q4 2022 reflecting 120 66% normalised manufacturing and distribution costs 100 63% 63% 64% 61% 99.5 62%
Slide 11: Continued growth in revenue and adjusted EBITDAR
Continued growth in revenue and adjusted EBITDAR1 First quarter of $100M revenue achieved Total revenue ($M) 120.0 • Revenue $100.1M, up 27% from $79.0M in the prior 100.0 100.1 quarter 80.0 79.0 60.0 • Total revenue is commercial sales of Illuccix plus all 57.1 40.0 other revenue (eg from pre-comme
Slide 12: Clinical Programs
Clinical Programs €) Telix
Slide 13: Core pipeline: Oncology and rare diseases
Core pipeline: Oncology and rare diseases Prostate PSMA1 PHASE 1 PHASE 2 PHASE 3 COMMERCIAL 68Ga Imaging Small molecule TLX591-CDx (68Ga-PSMA-11, Illuccix®) Antibody 177Lu Therapy TLX591 (177Lu-rosopatamab) Kidney CAIX2 PHASE 1 PHASE 2 PHASE 3 COMMERCIAL 89Zr Imaging Antibody TLX250-CDx (89Zr-girent
Slide 14: Research pipeline: novel targets and technologies
Research pipeline: novel targets and technologies ASSET TARGET ISOTOPE DESCRIPTION STATUS Immuno-oncology 177Lu TLX250 + Merck KGaA DNA Damage Response Inhibitor (DDRi) candidate in Phase Ib study (STARSTRUCK) TLX250 Combo CAIX patients with CAIX-expressing solid tumors to commence 1H 2023 Targeted
Slide 15: Clinical development highlights
Clinical development highlights Progress across multiple therapeutic trials Renal cancer imaging Prostate cancer Glioma imaging Rare diseases and therapy therapy and therapy portfolio • TLX250-CDx BLA and • ProstACT GLOBAL: • Positive consultation • Olaratumab (in- pre-commercialisation Preparation
Slide 16: TLX250-CDx: Featured at major medical congresses
TLX250-CDx: Featured at major medical congresses ZIRCON results presented to the medical community for the first time • Detailed analyses presented at prestigious international Dr Jeremie Calais, MD medical congresses ASCO-GU1 and EAU2 Director, Clinical Research • Data points support accuracy of th
Slide 17: TLX101-CDx for imaging of glioma
TLX101-CDx for imaging of glioma Positive feedback on U.S. regulatory strategy, intention to file NDA in 2023 confirmed Reduce and/or replace • TLX-101CDx has the potential to provide a rapid and conclusive Clear valuesurgical biopsies proposition for imaging 1 of glioma diagnosis of recurrent gliom
Slide 18: Radiolabelled olaratumab (TLX300) advancing to clinical trials
Radiolabelled olaratumab (TLX300) advancing to clinical trials Strong scientific, clinical and commercial rationale for development Olaratumab (Lartruvo®) was High unmet medical need for Olaratumab targets PDGFRα5 – commercialised by Lilly as a treatment of STS a promising target “naked” antibody1 •
Slide 19: Pre-clinical images show high uptake and retention in tumours
Pre-clinical images show high uptake and retention in tumours PET images1 of a single mouse at 24, 48 and 120 hours after dosing with 89Zr-TLX300-CDx Olaratumab radiolabelled with 89Zr with imaging and therapeutic radionuclide payloads demonstrate: • Tumour targeting • Tumour retention • Ability to
Slide 20: Upcoming catalysts
Upcoming catalysts Illuccix® - ProstACT Four key continued GLOBAL patient NDA for brain recruitment and BLA submission cancer imaging catalysts revenue growth for TLX250-CDx and global data readout (TLX101-CDx) rollout ProstACT SELECT EXPECTED MILESTONES 2023 Additional Illuccix® Prostate and Brusse
Slide 21: Thank you & questions
Thank you & questions Kyahn Williamson SVP Investor Relations and Corporate Communication kyahn.williamson@telixpharma.com 21
Telix Pharmaceuticals — Q1 2023 Earnings Presentation on 6ix